Stocks Health care APRE

NASDAQ · Health care

Aprea Therapeutics, Inc. (APRE)

It posted a net loss of $12.3M. At June 30, 2026 it held $41.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.

Watch APRE in 60 seconds

Follow APRE

Free, no password. An email when APRE files with the SEC.

Key facts about Aprea Therapeutics, Inc.

Net worth

Aprea Therapeutics, Inc. has a market value (market cap) of $5.6M at the latest share price, and shareholders' equity of $38.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Cash flow

In fiscal 2025 operations used $12.9M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

Next earnings report

Aprea Therapeutics, Inc.'s next report was expected around November 11, 2026 and is not on file with the SEC yet.

What Aprea Therapeutics, Inc. does

Aprea Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker APRE.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Aprea Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 28, 2026
   Other event 8-K
2. August 13, 2026
   Passive stake changed SCHEDULE 13G/A
3. August 12, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.07 versus -$0.53.
4. August 12, 2026
   Quarterly results 8-K
5. July 23, 2026
   Stock exchange listing notice 8-K
6. June 17, 2026
   Shareholder vote results 8-K
7. May 15, 2026
   Passive stake (5% or more) SCHEDULE 13G
8. May 13, 2026
   Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.22 versus -$0.66.
9. May 13, 2026
   Quarterly results 8-K
10. April 30, 2026
    Annual report to shareholders ARS

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 17, 2026. Insider transactions on SEC

Insider trades

What the people running Aprea Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns APRE

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Lytton Laurence W 3.2% (August 13, 2026); Nantahala Capital Management, LLC 4.5% (February 13, 2026); Sio Capital Management, LLC 1.93% (November 12, 2025); Stonepine Capital Management, LLC 4.3% (May 14, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

10 insiders reported holding 788,206 shares in total, about $352.2K at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about APRE

What does Aprea Therapeutics, Inc. do?

Aprea Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as APRE. Its shares trade on NASDAQ under the ticker APRE.

What is Aprea Therapeutics, Inc.'s net worth?

Aprea Therapeutics, Inc. has a market value (market cap) of $5.6M at the latest share price, and shareholders' equity of $38.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Aprea Therapeutics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $12.3M.

When did Aprea Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from August 28, 2026.

When is Aprea Therapeutics, Inc.'s next earnings report?

Aprea Therapeutics, Inc.'s next report was expected around November 11, 2026 and is not on file with the SEC yet.

Similar companies

Compare APRE with

Compare APRE with any company

Follow APRE

Get an email when Aprea Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow APRE

Free, no password. An email when APRE files with the SEC.

Where the numbers come from

Financial figures are the values Aprea Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.